Piroxicam analogue metal complexes: Synthesis, crystal structures, molecular modeling and biological studies

In recent decades, metal‐based drugs have gained considerable attention all over the world because of their enhanced therapeutic potential. The piroxicam analogue, that is, 2‐Benzyl‐4‐hydroxy‐1,1‐dioxo‐1,2‐dihydro‐1λ6‐benzo [e][1,2] thiazine‐3‐carboxylic acid pyridin‐2‐yl amide 1 was synthesized and coupled with Mn (II), Co (II), Ni (II), Cu (II) and Zn (II) metal ions to isolate complexes 2–6. The N,O‐bidentate chelator coordinated with the metal center via pyridyl nitrogen and amide oxygen atoms by forming six‐membered ring system. Several analytical techniques like UV–Vis, FT‐IR, 1H NMR, magnetic susceptibility, and elemental analysis were performed to confirm the syntheses of the octahedral complexes. The conductance measurement was employed to determine the non‐electrolytic nature of the complexes. The molecular structures of manganese (II) 2, cobalt (II) 3, and zinc (II) 6, complexes were confirmed by single beam X‐ray crystallography revealing the monoclinic crystal system with P21/c space group. The crystallographic data was utilized to carry out the DFT studies, which were found in line with the experimental data. The antioxidant (DPPH, FRAP) and antibacterial activities were performed to determine the therapeutic potential of these synthesized compounds. These studies indicated that understudied compounds have potential as therapeutic agents and they may be used as drug candidates in the future. The in‐silico studies also aligned with the in‐vitro potential of the targeted compounds.